Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyApar Kishor Ganti, Miranda Hughes, Charles Florsheim et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 459
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trialAssuntina G. Sacco, Ezra E.W. Cohen, Ruifeng Chen et al.|The Lancet Oncology|2021Cited by 257
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB StudySteven Powell, William C. Spanos, Kathryn A. Gold et al.|Journal of Clinical Oncology|2020Cited by 119
The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKLChristin Ungewiss, Don L. Gibbons, Zain H. Rizvi et al.|Scientific Reports|2016Cited by 74
A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinomaMichael J. Dennis, Kathryn A. Gold, Assuntina G. Sacco et al.|Oral Oncology|2022Cited by 21